IRINOTECAN AS A THIRD-LINE TREATMENT OF ADVANCED GASTRIC CANCER AFTER FAILURE OF FLUOROPYRIMIDINE, PLATINUM, AND TAXANES

被引：0
|
作者：
Nishimura, Takashi
Iwasa, Satoru
Shoji, Hirokazu
Okita, Natsuko
Takashima, Atsuo
Honma, Yoshitaka
Kato, Ken
Hamaguchi, Tetsuya
Yamada, Yasuhide
Shimada, Yasuhiro
机构：
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu435.40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1-17-5
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
    Takashi Nishimura
    Satoru Iwasa
    Kengo Nagashima
    Natsuko Okita
    Atsuo Takashima
    Yoshitaka Honma
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Yasuhiro Shimada
    Narikazu Boku
    Gastric Cancer, 2017, 20 : 655 - 662
  • [2] Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
    Nishimura, Takashi
    Iwasa, Satoru
    Nagashima, Kengo
    Okita, Natsuko
    Takashima, Atsuo
    Honma, Yoshitaka
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    Boku, Narikazu
    GASTRIC CANCER, 2017, 20 (04) : 655 - 662
  • [3] 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane
    Erdem, Gokmen Umut
    Bozkaya, Yakup
    Ozdemir, Nuriye Yildirim
    Demirci, Nebi Serkan
    Yazici, Ozan
    Zengin, Nurullah
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2018, 18 (02) : 170 - 177
  • [4] Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
    Makiyama, Akitaka
    Arimizu, Kohei
    Hirano, Gen
    Makiyama, Chinatsu
    Matsushita, Yuzo
    Shirakawa, Tsuyoshi
    Ohmura, Hirofumi
    Komoda, Masato
    Uchino, Keita
    Inadomi, Kyoko
    Arita, Shuji
    Ariyama, Hiroshi
    Kusaba, Hitoshi
    Shinohara, Yudai
    Kuwayama, Miyuki
    Kajitani, Tatsuhiro
    Oda, Hisanobu
    Esaki, Taito
    Akashi, Koichi
    Baba, Eishi
    GASTRIC CANCER, 2018, 21 (03) : 464 - 472
  • [5] Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
    Akitaka Makiyama
    Kohei Arimizu
    Gen Hirano
    Chinatsu Makiyama
    Yuzo Matsushita
    Tsuyoshi Shirakawa
    Hirofumi Ohmura
    Masato Komoda
    Keita Uchino
    Kyoko Inadomi
    Shuji Arita
    Hiroshi Ariyama
    Hitoshi Kusaba
    Yudai Shinohara
    Miyuki Kuwayama
    Tatsuhiro Kajitani
    Hisanobu Oda
    Taito Esaki
    Koichi Akashi
    Eishi Baba
    Gastric Cancer, 2018, 21 : 464 - 472
  • [6] Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer
    Takeshi Kawakami
    Nozomu Machida
    Hirofumi Yasui
    Masahiro Kawahira
    Sadayuki Kawai
    Yosuke Kito
    Yukio Yoshida
    Satoshi Hamauchi
    Takahiro Tsushima
    Akiko Todaka
    Tomoya Yokota
    Kentaro Yamazaki
    Akira Fukutomi
    Yusuke Onozawa
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 809 - 814
  • [7] Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer
    Kawakami, Takeshi
    Machida, Nozomu
    Yasui, Hirofumi
    Kawahira, Masahiro
    Kawai, Sadayuki
    Kito, Yosuke
    Yoshida, Yukio
    Hamauchi, Satoshi
    Tsushima, Takahiro
    Todaka, Akiko
    Yokota, Tomoya
    Yamazaki, Kentaro
    Fukutomi, Akira
    Onozawa, Yusuke
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (04) : 809 - 814
  • [8] Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival
    Eun Joo Kang
    Seock-Ah Im
    Do-Youn Oh
    Sae-Won Han
    Jin-Soo Kim
    In Sil Choi
    Jin Won Kim
    Yu Jung Kim
    Jee Hyun Kim
    Tae-You Kim
    Jong Seok Lee
    Yung-Jue Bang
    Keun-Wook Lee
    Gastric Cancer, 2013, 16 : 581 - 589
  • [9] Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival
    Kang, Eun Joo
    Im, Seock-Ah
    Oh, Do-Youn
    Han, Sae-Won
    Kim, Jin-Soo
    Choi, In Sil
    Kim, Jin Won
    Kim, Yu Jung
    Kim, Jee Hyun
    Kim, Tae-You
    Lee, Jong Seok
    Bang, Yung-Jue
    Lee, Keun-Wook
    GASTRIC CANCER, 2013, 16 (04) : 581 - 589
  • [10] Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
    Ishii, Takahiro
    Kawazoe, Akihito
    Sasaki, Akinori
    Mishima, Saori
    Kentaro, Sawada
    Nakamura, Yoshiaki
    Kotani, Daisuke
    Kuboki, Yasutoshi
    Taniguchi, Hiroya
    Kojima, Takashi
    Doi, Toshihiko
    Yoshino, Takayuki
    Kuwata, Takeshi
    Ishii, Genichiro
    Shitara, Kohei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
12345